LABELS · bf986b71-66e2-4883-9687-f340388abafe

Darzalex Faspro

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-09-03
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent high-risk smoldering multiple myeloma as monotherapy light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.3 ) 1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma. 1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Limitations of Use DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials [see Warnings and Precautions (5.2) ] .

Full extracted label fields

application numbers

BLA761145

boxed warning exact

brand names

Darzalex Faspro

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

bf986b71-66e2-4883-9687-f340388abafe

indications and usage exact

1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent high-risk smoldering multiple myeloma as monotherapy light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.3 ) 1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma. 1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Limitations of Use DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials [see Warnings and Precautions (5.2) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Janssen Biotech, Inc.

matched search terms

myeloma

package ndcs

57894-503-01

product ndcs

57894-503

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1 ) 1/2026 Dosage and Administration ( 2.2 ) 1/2026 Dosage and Administration ( 2.3 , 2.8 ) 11/2025 Warnings and Precautions ( 5.1 , 5.3 ) 11/2025

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2230
end exclusive: true
exact text: 1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent high-risk smoldering multiple myeloma as monotherapy light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or May
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 0

current approval status

not_reconciled

duplicate text group

dup-734b8277c6b09e080e52

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-83cf64ef6fd5ccabd24e

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

end: 157
end exclusive: true
exact text: is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 40

qualifier mentions

context exact
onidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lena
kind
age
polarity
not_inferred
span
end
193
end exclusive
true
exact text
adult patients
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
179
context exact
ND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the t
kind
biomarker
polarity
not_inferred
span
end
107
end exclusive
true
exact text
CD38-directed cytolytic antibody
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
75
context exact
le for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma i
kind
stage_or_setting
polarity
not_inferred
span
end
930
end exclusive
true
exact text
relapsed or refractory multiple myeloma who
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
887
context exact
ination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple
kind
stage_or_setting
polarity
not_inferred
span
end
1566
end exclusive
true
exact text
relapsed or refractory multiple myeloma who
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
1523
context exact
ibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent high-risk smoldering multiple myeloma as monotherapy lig
kind
stage_or_setting
polarity
not_inferred
span
end
1849
end exclusive
true
exact text
refractory to a PI and an immunomodulatory ag
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
1804
context exact
nd in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1104
end exclusive
true
exact text
who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for aut
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
927
context exact
n combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1388
end exclusive
true
exact text
who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
1211
context exact
ne in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are dou
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1740
end exclusive
true
exact text
who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
1563
context exact
for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide,
kind
regimen
polarity
not_inferred
span
end
396
end exclusive
true
exact text
in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant mu
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
217
context exact
igible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed
kind
regimen
polarity
not_inferred
span
end
590
end exclusive
true
exact text
in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
411
context exact
igible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
kind
regimen
polarity
not_inferred
span
end
911
end exclusive
true
exact text
in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory m
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
732
context exact
o have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received
kind
regimen
polarity
not_inferred
span
end
1168
end exclusive
true
exact text
in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination wit
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
989

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2030
end exclusive: true
exact text: 1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent high-risk smoldering multiple myeloma as monotherapy light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients.
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · limitation of use

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2488
end exclusive: true
exact text: mmunomodulatory agent high-risk smoldering multiple myeloma as monotherapy light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.3 ) 1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethas
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 1831

current approval status

not_reconciled

duplicate text group

dup-520e19126cf8e2a873fa

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-d306c64928d8633ae7c2

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2288
end exclusive: true
exact text: Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.3 )
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 2031

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · positive indication candidate

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 4272
end exclusive: true
exact text: s not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.3 ) 1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma. 1.3 Light Chain Amyloidosis DARZA
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 2089

current approval status

not_reconciled

duplicate text group

dup-3ec7d49c49b291d5953b

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-40119ff65dde003789d9

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

end: 2338
end exclusive: true
exact text: is indicated
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 2326

qualifier mentions

context exact
e Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in com
kind
age
polarity
not_inferred
span
end
2374
end exclusive
true
exact text
adult patients
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
2360
context exact
le for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma
kind
stage_or_setting
polarity
not_inferred
span
end
3144
end exclusive
true
exact text
relapsed or refractory multiple myeloma who
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3101
context exact
ination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple
kind
stage_or_setting
polarity
not_inferred
span
end
3784
end exclusive
true
exact text
relapsed or refractory multiple myeloma who
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3741
context exact
ibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
kind
stage_or_setting
polarity
not_inferred
span
end
4068
end exclusive
true
exact text
refractory to a PI and an immunomodulatory ag
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
4023
context exact
nd in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma in combination with bortezomib, thalidomi
kind
prior_therapy_or_line
polarity
not_inferred
span
end
3185
end exclusive
true
exact text
who have received at least one prior therapy
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3141
context exact
n combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. multiple myeloma in combination with pomalidomide and dexa
kind
prior_therapy_or_line
polarity
not_inferred
span
end
3471
end exclusive
true
exact text
who have received at least one prior therapy
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3427
context exact
combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. multiple myeloma in combination with carfilzomib and dexam
kind
prior_therapy_or_line
polarity
not_inferred
span
end
3655
end exclusive
true
exact text
who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3553
context exact
ne in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple myeloma as monotherapy, in patients who have rece
kind
prior_therapy_or_line
polarity
not_inferred
span
end
3834
end exclusive
true
exact text
who have received one to three prior lines of therapy
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3781
context exact
es of therapy. multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
4058
end exclusive
true
exact text
who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomod
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
3881
context exact
tients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidom
kind
regimen
polarity
not_inferred
span
end
2604
end exclusive
true
exact text
in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
2428
context exact
gible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan
kind
regimen
polarity
not_inferred
span
end
2769
end exclusive
true
exact text
in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
2623
context exact
gible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with lenalidomide and dexa
kind
regimen
polarity
not_inferred
span
end
2927
end exclusive
true
exact text
in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
2788

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 4072
end exclusive: true
exact text: 1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 2289

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · positive indication candidate

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 4438
end exclusive: true
exact text: atients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma. 1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) a
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 3873

current approval status

not_reconciled

duplicate text group

dup-ec45e971f160603b93e1

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-e34ef28a815bbb568e33

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

end: 4158
end exclusive: true
exact text: is indicated
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4146

qualifier mentions

context exact
LEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma.
kind
age
polarity
not_inferred
span
end
4194
end exclusive
true
exact text
adult patients
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
4180
context exact
1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma.
kind
regimen
polarity
not_inferred
span
end
4237
end exclusive
true
exact text
as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
4131

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 4238
end exclusive: true
exact text: 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma.
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4073

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · positive indication candidate

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 4649
end exclusive: true
exact text: PI and an immunomodulatory agent. 1.2 High-Risk Smoldering Multiple Myeloma DARZALEX FASPRO as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma. 1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Limitations of Use DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4039

current approval status

not_reconciled

duplicate text group

dup-20b183e0c0df52e2acec

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-a919d7c639807df9e13c

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

end: 4362
end exclusive: true
exact text: is indicated
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4350

qualifier mentions

context exact
phamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
kind
age
polarity
not_inferred
span
end
4398
end exclusive
true
exact text
adult patients
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
4384
context exact
1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
kind
regimen
polarity
not_inferred
span
end
4448
end exclusive
true
exact text
in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis
label id
bf986b71-66e2-4883-9687-f340388abafe
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start
4283

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 4449
end exclusive: true
exact text: 1.3 Light Chain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4239

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · limitation of use

application numbers

BLA761145

brand names

Darzalex Faspro

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 4738
end exclusive: true
exact text: hain Amyloidosis DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Limitations of Use DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials [see Warnings and Precautions (5.2) ] .
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4250

current approval status

not_reconciled

duplicate text group

dup-f343152b7e9ff407341f

extraction review status

automated_candidate_pending_source_review

generic names

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

ind-span-2ee24f8138ecf3917798

label id

bf986b71-66e2-4883-9687-f340388abafe

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 4738
end exclusive: true
exact text: Limitations of Use DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials [see Warnings and Precautions (5.2) ] .
label id: bf986b71-66e2-4883-9687-f340388abafe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 68a46f6f825422b9a48435a6407494bef5a3afd14e061c7053d2336550c95324
start: 4450

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bf986b71-66e2-4883-9687-f340388abafe%22

spl effective date

2026-09-03

spl set id

4bb241af-4299-4373-8762-2d6709515db0

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice